Podcasts about Fibrosis

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Sven Francque, MD, PhD - The Gastroenterologist's Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Sven Francque, MD, PhD - The Gastroenterologist's Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Sven Francque, MD, PhD - The Gastroenterologist's Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Sven Francque, MD, PhD - The Gastroenterologist's Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Sven Francque, MD, PhD - The Gastroenterologist's Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Sven Francque, MD, PhD - The Gastroenterologist's Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Sven Francque, MD, PhD - The Gastroenterologist's Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Sven Francque, MD, PhD - The Gastroenterologist's Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Are you up to date on the latest noninvasive screening tools for MASH fibrosis? Credit available for this activity expires: 5/13/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/noninvasive-assessment-mash-fibrosis-2026a1000f5l?ecd=bdc_podcast_libsyn_mscpedu

Research Examines the Connection Between Periodontitis and Atrial Fibrosis in Atrial FibrillationBy Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/research-examines-the-connection-between-periodontitis-and-atrial-fibrosis-in-atrial-fibrillation/Need CE? Start earning CE credits today at ⁠⁠⁠https://rdh.tv/ce⁠⁠⁠ Get daily dental hygiene articles at ⁠⁠⁠https://www.todaysrdh.com⁠⁠⁠ Follow Today's RDH on Facebook: ⁠⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠⁠Follow Kara RDH on Facebook: ⁠⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠⁠Follow Kara RDH on Instagram: ⁠⁠⁠https://www.instagram.com/kara_rdh/⁠

In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsGeorg Vo Beiske, CEO, Tribune TherapeuticsJonas Hallén, Co-Founder & CMO, Calluna PharmaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Contributor: Taylor Lynch, MD Educational Pearls:    Conduction abnormalities are a common and clinically significant complication in patients who undergo transcatheter aortic valve replacement (TAVR)   Clinical Features The most common abnormalities include high grade AV block and new onset LBBB  Due to the close proximity of the aortic annulus to the AV node and His-Purkinje system More common in males, the elderly, and those with pre-existing conduction disease (RBBB or LBBB) Sinus pauses and sinus arrest are a rare post-TAVR rhythm disturbances Temporary failure of sinus node firing with absent P waves, followed by return of sinus rhythm Sinus Pauses: Typically last < 3 seconds Sinus Arrest: Typically last > 3 seconds Not due to direct mechanical injury from the valve, but may occur in patients as a result of pre-existing disease or other external factors: Medications Beta blockers, calcium channel blockers, digoxin Pre-existing damage to the SA node Fibrosis from a previous MI   Treatment If the patient is asymptomatic, provide ongoing surveillance If the patient is symptomatic, treatment should be aimed at the underlying cause: For medication-induced abnormalities, stop the offending medication For acute, unstable bradycardia: Medications: Atropine, Dopamine Infusion, Epinephrine Infusion If cardiology is not immediately available, initiate transcutaneous pacing or insert a temporary transvenous pacemaker Definitive treatment: Pacemaker ~10–15% of patients may develop a bradyarrhythmia post TAVR, with ~8-15% later requiring a pacemaker   Due to the risk of conduction abnormalities post TAVR, many patients are discharged with ambulatory rhythm monitoring such as a ZioPatch or Holter monitor, and may present to the emergency department for evaluation of rhythm disturbances.   Donate: https://emergencymedicalminute.org/donate/   Join our mailing list: http://eepurl.com/c9ouHf  

Drs. Swigris and Humphries discuss how data-driven texture analysis (DTA) on HRCT enables precise, objective quantification of fibrotic burden in ILD, overcoming the limitations of semi-quantitative visual scoring and blunt physiologic measures. They further describe a complementary AI-based classifier that predicts histologic usual interstitial pneumonia (UIP) patterns from CT, enhancing prognostication and potentially reducing the need for surgical lung biopsy.

Aging has long been linked to a range of biological processes, including cellular senescence, epigenetic changes, and chronic tissue remodeling. Yet, these explanations often describe what happens during aging rather than why certain age-related diseases, such as fibrosis, continue to progress over time. In conditions like idiopathic pulmonary fibrosis (IPF), a key question remains: what drives the persistent activation of cells that should normally return to a resting state after injury? Increasing attention has turned to the interaction between cellular signaling pathways and epigenetic regulation as a potential explanation. Understanding how these processes work together to control gene expression and cell behavior is becoming an important focus in uncovering the mechanisms behind age-related disease. A new research paper was published in Volume 18 of Aging-US, titled “P38 MAPK is involved in epigenetic regulation of fibrotic genes in replication induced senescence in lung fibroblasts.” The study was led by first author Shan Zhu and corresponding author Yan Y. Sanders from the Department of Biomedical and Translational Sciences, Eastern Virginia Medical School (Macon & Joan Brock Virginia Health Sciences at Old Dominion University), in collaboration with Jennifer Q. Zhou, Kan Wang, and Ming-lei Guo from the same institution. Full blog - https://aging-us.org/2026/04/p38-mapk-driven-epigenetic-regulation-identified-as-a-key-mechanism-in-lung-fibrosis/ Paper DOI - https://doi.org/10.18632/aging.206357 Corresponding author - Yan Y Sanders - sandery@odu.edu Abstract video - https://www.youtube.com/watch?v=yP0CwWMUhnY Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206357 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, senescence, fibroblast activation, p38 MAPK, lung fibrosis, H4K16Ac To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this replay episode from 2 years ago, we delve into the world of adult congenital heart disease to review the topic of liver disease in the Fontan patient and specifically, hepatocellular carcinoma (HCC). What is the prevalence of this disease in the Fontan single ventricle adult patient? How effective are scores like the MELD-XI or Fibrosis-4 Index at identification of HCC in the Fontan patient? How should the Fontan adult patient be surveilled for this form of cancer? What evidence is there that earlier identification of HCC is associated with better outcomes? What may prove to be the most important factor in protection of the liver in the Fontan patient? Dr. Yuli Kim, Director of the ACHD program at The University of Pennsylvania shares her deep insights this week into this important topic.DOI: 10.1093/eurheartj/ehad788

Deputy Editor Kenneth Ellenbogen presents an in‑depth discussion of the study "Long PR Interval Leads to Atrial Remodeling, Fibrosis and Inducible Atrial Fibrillation in a Swine Model." In this episode, Dr. Ellenbogen walks listeners through how prolonged atrioventricular conduction can drive structural and electrical remodeling in the atria, leading to fibrosis and increased susceptibility to atrial fibrillation. He highlights the significance of these findings for understanding AF pathophysiology and considers how this preclinical model may inform future prevention and treatment strategies.

Send Us Your Prayer Requests --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

This week, the MRI showed that I have post-surgical epidural fibrosis over my L4 left thecal sac and left L4 nerve root! That is the likely cause of my continuing femoral nerve pain. I will see the neurosurgeon this week to find out next steps. Meanwhile, I’ve gotten going on a number of natural remedies to […]

¿Has pasado por un tratamiento de radioterapia tras un diagnóstico de cáncer de mama? ¿Qué efectos secundarios has sufrido o sigues padeciendo? La fibrosis es uno de los efectos secundarios principales y en este episodio Saioa nos habla de terapias complementarias y de diferentes estudios realizados acerca de la fibrosis.

Send us Fan MailThe science, hype, and unknowns surrounding popular peptides like BPC-157 & TB-500 ("Wolverine stack") for injury recovery & tissue repair.Nick & Dr. Flynn McGuire discuss the surge in peptide use for injury recovery. They cover peptide basics, the preclinical evidence for BPC-157 and TB-500, mechanisms like angiogenesis and tissue repair, the lack of robust human trials, sourcing risks, regulatory bans, and the gap between anecdotal reports and scientific certainty.TOPICS DISCUSSED:Peptide basics: Short amino acid chains (e.g., insulin, GLP-1 agonists); BPC-157 derived from gastric juice, TB-500 a fragment of thymosin beta-4.Rise in popularity: Driven by podcasts, social media, biohacking culture, and post-COVID distrust in institutions; “bro science” often precedes formal research.BPC-157 mechanisms: Pleiotropic effects including VEGF upregulation, nitric oxide pathways, angiogenesis, reduced fibrosis, and possible neuromuscular stabilization.TB-500 & “stacking”: Often combined with BPC-157 for presumed synergy; marketed as “Wolverine stack” for rapid healing.Evidence limitations: Strong rodent data for tendon/muscle repair, but almost no high-quality human trials; one small retrospective study and ongoing phase 2 trial in China.Safety and risks: Unknown long-term effects, potential cancer concerns via angiogenesis; no established dosing, potency, or administration route in humans.Sourcing & quality issues: Often obtained as “research chemicals” online; variable purity, stability concerns, no reliable regulation or third-party verification for most users.ABOUT THE GUEST: Flynn Mcguire, MD is a physical medicine and rehabilitation resident at the University of Utah; he conducts clinical work in neurologic recovery and musculoskeletal care and has authored a narrative reviews on peptides for musculoskeletal healing.RELATED EPISODE:M&M 252: Scarring, Fibrosis, Oxidative Stress, and Psilocybin & Aging | Louise HeckerReference Paper:Paper | Regeneration or Risk? A Narrative Review of BPC-157 for MusculoskeleSupport the showHealth Products by M&M Partners:SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off.Lumen device: Optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off.AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models.Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app.KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime)For all the ways you can support my efforts

Send us Fan MailPaper Discussed in this Episode:Assessing interstitial fibrosis and tubular atrophy in kidney biopsies artificial intelligence versus humans. Farris AB, Zukić D, Solez K. Current Opinion in Nephrology and Hypertension. March 16, 2026.Episode Summary: In this journal club deep dive on the Digital Pathology Podcast, we explore the intense debate over quantifying chronic kidney disease progression. We unpack a fresh 2026 study comparing artificial intelligence to human pathologists in assessing interstitial fibrosis and tubular atrophy. If top experts can't agree on a diagnosis due to human subjectivity, can an AI trained on their imperfect data provide a better standard? We explore what happens when pixel-perfect machines clash with nuanced human medical judgment.In This Episode, We Cover:• The Clinical Stakes of Kidney Scarring: Why interstitial fibrosis (the scarring of tissue spaces between filtering units) and tubular atrophy (shrinking and collapsing functional tubes) are the primary surrogate measures for tracking chronic kidney disease. We discuss how a mere 10% diagnostic variance can drastically alter a patient's medication regimen, dialysis prep, or transplant eligibility.• The Flaw in the "Gold Standard": We break down the "interobserver variability" problem—why two highly trained, board-certified pathologists can look at the exact same biopsy slide and give two completely different mathematical assessments of the damage.• How the AI Actually Works (Mapping the Neighborhood): A look at "indirect assessment through kidney compartment segmentation," where the AI acts as a digital surveyor. It identifies cellular fences like glomeruli and tubules, establishing microscopic "zoning laws" before it begins counting the damaged tissue.• The Proofreader vs. The Literary Critic: Why studies show a persistent "lack of complete concordance" between human and machine. We discuss how AI hyper-focuses on mathematical pixel intensity and mistakes physical slide artifacts (like a folded piece of tissue) for severe disease. Meanwhile, human pathologists act as "literary critics," easily filtering out the visual noise using clinical context.• The Humans + AI Synergy: The ultimate endgame isn't replacing pathologists, but combining the tireless mathematical consistency of AI with the complex contextual reasoning of humans to create a highly advanced co-pilot system.Key Takeaway: The lack of perfect agreement between AI and human pathologists isn't a failure, but rather evidence that they perform fundamentally different types of analysis. AI excels at tedious, reproducible quantification that eliminates human visual fatigue, but it lacks contextual judgment. By adopting a "humans + AI" workflow, the medical field can stabilize crucial kidney measurements and elevate the pathologist to a true diagnostic synthesizer, ultimately leading to more effective patient careSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

My Mistake! – If you’re looking for the show notes for the show we did with Karen Urbanek, please click here!

The second ousting of Vinay Prasad from FDA in the past eight months won't lead to major changes at the agency, other than selecting a successor tasked with keeping FDA out of the news ahead of the coming midterm elections. On the latest BioCentury This Week podcast, Washington editor Steve Usdin lays out why the former CBER director was pushed out at FDA and what's next for the agency following his departure.BioCentury's editors also discuss the next wave of therapies for idiopathic pulmonary fibrosis, including whether new candidates might go beyond slowing disease to halt or even reverse progression, the biological complexity that makes fibrosis so challenging, and what the 20-plus Phase II programs could teach the field about fibrosis biology.Also up for discussion were recent clinical wins — as well as more complicated readouts — from psychedelic therapies; plus the latest data updates from obesity treatments, with a focus on amylin agonists.View full story: https://www.biocentury.com/article/658698#FDA #IdiopathicPulmonaryFibrosis #PsychedelicTherapies #ObesityDrugs #AmylinAgonists00:00 - Introduction01:56 - Prasad's Departure15:27 - Fibrosis Therapies23:35 - Psychedelics Clinical Catalysts28:24 - Obesity UpdatesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this hot health topic episode of Accelerated Health with Sara Banta, I talk about new research linking liver health to cancer risk and liver fibrosis—and why this connection is getting serious attention in the health world.I break down how liver dysfunction, fatty liver, toxin overload, and chronic inflammation may contribute to the development of fibrosis and even cancer, often long before symptoms appear. Many people focus on weight or digestion, but the liver plays a central role in metabolism, detoxification, and overall health.If you're dealing with fatty liver, metabolic issues, fatigue, or toxin exposure, this episode highlights why protecting your liver could be one of the most important things you do for your long-term health.Watch this episode highlight to learn more about the powerful connection between liver health, fibrosis, and cancer risk.Supplements Featured In This Episode:• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Accelerated Cellular Detox® Powder https://www.acceleratedhealthproducts.com/products/accelerated-cellular-detox-powder • Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Flush Detox Cleanse https://www.acceleratedhealthproducts.com/products/liver-detox-cleanse Not sure what food to eat and avoid? This guide is for you.⬇️

In this episode, we're discussing early Get Out vibes, asbestos awareness, Mulder's tailor and the FBI's only doctor. That's right, we're taking a deep dive into season four episode three, Teliko. If you'd like to feature in our next episode then tweet us @TheMSRFilesPod or send your emails to TheMSRFilesPodcast@GMail.com where you can also send in your own paranormal stories to feature in our next Do You Think I'm Spooky? Segment. Also, don't forget to check us out on Instagram and TikTok @TheMSRFilesPodcast 

 Interstitial Lung Abnormality (ILA) and Interstitial Lung Disease (ILD) are often detected using CT scans and other imaging. But the definition of ILAs and how abnormalities are found throughout a patient's clinical journey continues to grow and improve. Host Eddie Qian, MD, Vanderbilt University Medical Center, discusses the importance of spotting ILAs and diagnosing ILDs earlier for better patient outcomes with experts Anna Podolanczuk, MD, Weill Cornell Medical Center, and Joe Mammarappallil, MD, Duke University. This episode is sponsored in part by Boehringer Ingelheim. Read "Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement": https://www.atsjournals.org/doi/10.1164/rccm.202505-1054ST 

Is breakfast the most important meal of the day, or should you skip it altogether? Stop the morning habits that harm your liver and try my liver health tips to improve liver function and overall health instead.

Drs. Adegunsoye and Kaul review their takeaways from CHEST 2025, where pulmonary experts revealed a transformative approach to interstitial lung disease that emphasizes precision medicine and personalized treatments. The conference marked a shift from passive observation to proactive intervention, focusing on early screening, targeted therapies, and reducing healthcare disparities.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WDQ865. CME/AAPA credit will be available until November 25, 2026.Fibrosis, Flares, and Forward Thinking in Inflammatory Bowel Disease Care: Unlocking the TL1A Axis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WDQ865. CME/AAPA credit will be available until November 25, 2026.Fibrosis, Flares, and Forward Thinking in Inflammatory Bowel Disease Care: Unlocking the TL1A Axis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WDQ865. CME/AAPA credit will be available until November 25, 2026.Fibrosis, Flares, and Forward Thinking in Inflammatory Bowel Disease Care: Unlocking the TL1A Axis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WDQ865. CME/AAPA credit will be available until November 25, 2026.Fibrosis, Flares, and Forward Thinking in Inflammatory Bowel Disease Care: Unlocking the TL1A Axis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WDQ865. CME/AAPA credit will be available until November 25, 2026.Fibrosis, Flares, and Forward Thinking in Inflammatory Bowel Disease Care: Unlocking the TL1A Axis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WDQ865. CME/AAPA credit will be available until November 25, 2026.Fibrosis, Flares, and Forward Thinking in Inflammatory Bowel Disease Care: Unlocking the TL1A Axis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

One in three adults now has fatty liver disease, and most don't even know it. It's become the most common form of liver dysfunction worldwide—even outpacing alcohol-related liver damage. And the real danger? It often progresses in silence, from fat to inflammation to fibrosis, with no symptoms until it's too late.In this episode of ReInvent Healthcare, Dr. Ritamarie exposes a quiet transformation that's becoming alarmingly common: the metabolic cascade behind fatty liver. It doesn't start with pain or obvious signs. It starts with subtle shifts in biochemistry that most protocols completely miss.Before the liver scars, there are clues. And if you know where to look, you can help reverse the damage long before it becomes permanent.What's Inside This Episode? Why liver damage is now driven more by food than by alcoholThe signals that mark the shift from fat accumulation to fibrosisWhat “normal” AST and ALT might be hiding, and how to interpret themA critical lab ratio that reveals what single values can'tEarly metabolic signs that point to liver inflammation before imaging shows a thingTherapeutic strategies to restore liver function, starting with the kitchenHow trauma and oxytocin tie into liver recoveryThe botanical allies that protect and regenerate hepatic tissueResources and Links:Download our FREE Metabolic Health Guide here. Check out the FREE From Fat to Fibrosis Practitioner Quick GuideHere is a FIB-4 Calculator Tool FIB-4 = (Age × AST) / (Platelets × √ALT)NAFLD fibrosis score (NFS) = -1.675 + (0.037 × age) + (0.094 × BMI) + (1.13 × hyperglycemia) + (0.99 × AST/ALT ratio) - (0.013 × platelet count) - (0.66 × albumin)Join the Next-Level Health Practitioner Facebook group here for free resources and community supportVisit INEMethod.com for advanced health practitioner training and tools to elevate your clinical skills and grow your practice by getting life-changing results. Check out other podcast episodes here

Dr. Jack Cush reviews the news and journal articles from RheumNow.com.  Pool therapy, Fibrosis, NSIE's and whats best for knee OA.

Send us a textAging, tissue repair, and the longevity benefits of psilocin.Episode Summary: Dr. Louise Hecker discusses her research on tissue repair and regeneration, explaining how fibroblasts drive wound healing by forming scar tissue but fail to resolve properly with age, leading to fibrotic diseases like pulmonary fibrosis and liver cirrhosis; they discuss aging hallmarks such as oxidative stress and telomere shortening, and highlight Hecker's study showing psilocybin's active metabolite, psilocin, extends cellular lifespan in lab cultures by reducing oxidants and preserving telomeres, while monthly doses in aged mice improved appearance and survival rates.About the guest: Louise Hecker, PhD is an Associate Professor of Medicine at Baylor College of Medicine, specializing in repair and regeneration processes, particularly in aging and fibrotic diseases.Discussion Points:Fibroblasts are dormant cells that activate during injury to pull wounds closed and form scars, then de-differentiate or die; aging impairs this, causing persistent scarring and disease.Aging reduces the body's regenerative capacity; different organs vary in repair efficiency, with skin healing better than heart tissue.Oxidative stress, like "rust" in the body, accumulates with age due to imbalanced reactive oxygen species production and antioxidant defenses, contributing to cellular damage.Telomeres act as protective DNA caps that shorten with cell divisions, serving as a hallmark of biological aging; sirtuins are master regulators influencing aging processes.Hecker's in vitro study showed psilocin dose-dependently extended fibroblast lifespan by 29-50%, lowering oxidative stress below young cell levels and preserving telomeres.In aged mice (equivalent to 60-65 human years), monthly high-dose psilocybin (15 mg/kg) led to healthier appearance, regrown fur, and 80% survival when controls reached 50% mortality after 10 months.Psilocybin's effects may stem from serotonin receptors expressed in many cell types beyond the brain, suggesting broader anti-aging potential; future work explores mechanisms, optimal dosing, and applications for age-related diseases.Fungi like magic mushrooms represent an under-explored "kingdom" for medicine, with psilocybin's durable effects hinting at systemic impacts on aging.Reference Paper:Study: Psilocybin treatment extends cellular lifespan and improves survival of aged miceRelated content:Support the showAffiliates: Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. For all the ways you can support my efforts

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40447]

The FDA has granted accelerated approval to semaglutide (Wegovy) as the first drug for metabolic dysfunction–associated steatohepatitis (MASH), showing significant improvements in liver health and weight loss in the phase 3 ESSENCE trial. A systematic review of acetaminophen use in pregnancy found potential risks with long-term or frequent use but confirmed short-term, low-dose use remains appropriate when needed. Finally, an AI model integrating MRI, biomarkers, and clinical data improved prediction of knee osteoarthritis progression, enhancing physician accuracy and suggesting future support for earlier, personalized interventions.

If you're curious as to if you have any stored emotions or trauma that might be causing your illness, preventing you from achieving your or even just showing up as the best, authentic version of yourself, I invite you to take my free Stored Emotions and Trauma Quiz How often do you think about your kidneys?In this episode, I sit down with Dr. Robin Rose, a longtime voyager and pioneer in conscious and holistic healing whose path went from nursing to nurse practitioner to medical school. Her passion for kidney health was sparked by her own experience with kidney cancer and kidney disease, and the decade-long recovery that led her to a new paradigm she calls phenology, the art and clinical science of kidney success.We talk about exactly what to look for in labs (including how to think about GFR), the emotional and spiritual energetics behind kidney dysfunction, and the top lifestyle moves to make when kidney function isn't where it should be. We also get into why kidneys are so often overlooked in medicine and how Dr. Rose rebuilt her health after a nephrectomy. You'll Learn:Labs to consider for assessing kidney healthWhat a healthy GFR level isEnergetics, emotional, and spiritual aspects underlying kidney dysfunction and diseaseTop 10 lifestyle changes for poor kidney functionThe hidden early signs of kidney decline most doctors missHow conventional and even functional medicine often overlook kidney healthKey lifestyle shifts that can improve kidney performance and energy levelsThe quiet damage high animal protein diets can cause in compromised kidneysWhat it feels like to rebuild health after losing a kidneyHow spiritual practices and mindset can influence physical healingThe overlooked role of kidney tubules and how to test their functionPractical ways to reduce kidney-toxic exposures in daily lifeTimestamps: [00:00] Introduction [05:44] Robin shares her journey through illness, surgery, and kidney cancer diagnosis [14:59] Discovering functional and regenerative approaches to improve GFR [24:53] Emotional, spiritual, and energetic aspects of kidney health [34:27] Why kidneys are often overlooked in conventional and functional medicine [42:58] Understanding kidney tubules and overlooked testing options [53:22] Diet changes that protect kidney function and common mistakes to avoid [1:02:47] Reducing toxins and environmental exposures that harm kidneys [1:12:55] Mindset, self-love, and adapting to support long-term healing [1:21:40] Key lifestyle factors for kidney regeneration and successResources Mentioned:Renology Peptides by Robin Rose | BookLearn more from Robin by checking out her websiteFind More From Dr. Stephanie Davis:Dr. Stephanie Davis | WebsiteQuantum Rx | InstagramQuantum Rx | Skool